

RENAL RISK MINIMISATION MATERIAL: TENOFOVIR DISOPROXIL FOR ADOLESCENT CHILDREN WITH CHRONIC HEPATITIS B

This brochure provides important advice on the management of potential renal and bone effects of tenofovir disoproxil in adolescent patients with chronic hepatitis B aged 12 to <18 years, and on the dosing recommendations for tenofovir disoproxil in this population.

Important points to consider

- A multidisciplinary approach is recommended for the management of adolescents
- Check all patients' creatinine clearance and serum phosphate before starting tenofovir disoproxil therapy
- During tenofovir disoproxil therapy, renal function (creatinine clearance and serum phosphate) should be assessed regularly (after two to four weeks of treatment, after three months of treatment and every three to six months thereafter in patients without renal risk factors) (see Table 1)
- In patients at risk for renal impairment a more frequent monitoring of renal function is required
- Tenofovir disoproxil should not be used in adolescents with renal impairment
- Re-evaluate renal function within 1 week if serum phosphate is confirmed to be <3.0 mg/dL (0.96 mmol/L) during tenofovir disoproxil therapy
- If renal abnormalities are suspected or detected, consult with a nephrologist to consider interrupting tenofovir disoproxil therapy. Also consider interrupting treatment with tenofovir disoproxil in case of progressive decline of renal function when no other cause has been identified
- Avoid concurrent or recent use of nephrotoxic medicinal products
- Tenofovir disoproxil may cause a reduction in bone mineral density (BMD). The effects of tenofovir disoproxil associated changes in BMD on long term bone health and future fracture risk are currently unknown in adolescents
- If bone abnormalities are suspected or detected, consult with an endocrinologist and/or a nephrologist

Management of renal effects

There are uncertainties associated with the long-term effects of bone and renal toxicity. Moreover, the reversibility of renal toxicity cannot be fully ascertained. Therefore, a multidisciplinary approach is recommended to adequately weigh on a case by case basis the benefit/risk balance of treatment, decide the appropriate monitoring during treatment (including decision for treatment withdrawal) and consider the need for supplementation.

In clinical studies and post-marketing safety surveillance of tenofovir disoproxil in adults, events of renal failure, renal impairment, and proximal renal tubulopathy (including Fanconi syndrome) have been reported. In some patients proximal renal tubulopathy has been associated with myopathy, osteomalacia (manifested as bone pain and infrequently contributing to fractures), rhabdomyolysis, muscle weakness, hypokalaemia and hypophosphataemia.

Tenofovir disoproxil is not recommended for use in adolescents with renal impairment. Tenofovir disoproxil should not be initiated in adolescents with renal impairment and should be discontinued in adolescents who develop renal impairment during tenofovir disoproxil therapy.

The recommendations for monitoring renal function in adolescent patients without renal risk factors prior to and during tenofovir disoproxil therapy are provided in Table 1. In patients at risk for renal impairment a more frequent monitoring of renal function is required.

Table 1: Monitoring of renal function in patients without renal risk factors

	Prior to tenofovir disoproxil	During 1 st 3 months on tenofovir disoproxil	>3 months on tenofovir disoproxil
Frequency	At baseline	At 2 to 4 weeks and 3 months	Every 3 to 6 months
Parameter	Creatinine clearance and serum phosphate	Creatinine clearance and serum phosphate	Creatinine clearance and serum phosphate

If serum phosphate is confirmed to be <3.0 mg/dL (0.96 mmol/L), renal function should be re-evaluated within one week, including measurements of blood glucose, blood potassium and urine glucose concentrations. If renal abnormalities are suspected or detected then consultation with a nephrologist should be obtained to consider interruption of tenofovir disoproxil treatment. Also consider interrupting treatment with tenofovir disoproxil in case of progressive decline of renal function when no other cause has been identified.

Use of tenofovir disoproxil should be avoided with concurrent or recent use of a nephrotoxic medicinal product and drugs secreted by the same pathway; if concomitant use is unavoidable, renal function should be monitored weekly. Cases of acute renal failure after initiation of high dose or multiple non-steroidal anti-inflammatory drugs (NSAIDs) have been reported in patients treated with tenofovir disoproxil and with risk factors for renal dysfunction. If tenofovir

disoproxil is co-administered with an NSAID, renal function should be monitored adequately.

Management of bone effects

Tenofovir disoproxil may cause a reduction in bone mineral density (BMD).

Reductions in BMD have been reported in HBV infected adolescents. The BMD Z-scores observed at 72 weeks in subjects who received tenofovir disoproxil were lower than those observed in subjects who received placebo. The effects of tenofovir disoproxil associated changes in BMD on long term bone health and future fracture risk are currently unknown. If bone abnormalities are suspected or detected, then consultation with an endocrinologist and/or a nephrologist should be obtained.

Dosing recommendations for tenofovir disoproxil in adolescents

Tenofovir disoproxil 245 mg film-coated tablets are approved for the treatment of chronic hepatitis B in adolescents 12 to <18 years of age and weighing ≥35 kg with compensated liver disease and evidence of immune active disease, i.e. active viral replication, persistently elevated serum ALT levels and histological evidence of active inflammation and/or fibrosis. No data are currently available in children with chronic hepatitis B aged 2 to <12 years or weighing <35 kg.

In adolescents aged 12 to <18 years in whom a solid dosage form is not appropriate, tenofovir disoproxil is also available as 33 mg/g granules. The recommended dose of tenofovir disoproxil for the treatment of chronic hepatitis B in adolescents aged 12 to <18 years and weighing ≥35 kg is 245 mg, equivalent to 7.5 scoops of granules, once daily.